Fedrilate is a mucolytic drug. It was patented in 1963 and claimed to have a noteworthy anti-tussive activity.

Trimazosin was originated by Pfizer and was licensed to Bristol-Myers Squibb worldwide except for Canada, Mexico and the USA. Trimazosin is a quinazoline antihypertensive agent structurally related to the selective alpha 1-adrenoceptor blocker prazosin. Trimazosin is an alpha adrenergic receptor antagonist. Compared with prazosin, trimazosin was a less potent but more efficacious hypotensive agent. At doses which caused equal or even greater hypotensive effects than those caused by prazosin, trimazosin caused less inhibition of pressor responses to phenylephrine. When administered during a maximum hypotensive response to prazosin, trimazosin caused an additional fall in pressure. Trimazosin is an effective antihypertensive when given by itself or in combination with a diuretic. Its ability to induce vasodilation without concomitant sodium retention or stimulation of the renin axis may be an important factor in its effectiveness. Trimazosin has the potential to cause sustained improvement in left ventricular function, both at rest and during exercise, in patients with chronic congestive heart failure (CHF).

Disodium iminodiacetate is a salt of iminodiacetic acid (IDA). The iminodiacetate anion can act as a tridentate ligand to form a metal complex with two, fused, five-membered chelate rings. Iminodiacetic acid is used to diagnose problems of the liver, gallbladder and bile ducts in an imaging procedure, called as hepatobiliary iminodiacetic acid (HIDA) scan. A nuclear medicine scanner tracks the flow of the tracer from the liver into the gallbladder and small intestine and creates computer images. In addition, iminodiacetate is a part of the iminodiacetate-modified poly-L-lysine dendrimer (IMPLD), a fluorescent bone-imaging agent. IMPLD is used in the diagnosis of bone tumors, or to be used for the delivery of chemotherapy drugs or therapeutic agents. Bones differ from other body tissues in their unique calcium mineral composition, which consists mainly of hydroxyapatite (HA). IDA functionalization could be used as a general approach to bone targeting by increasing affinity for HA, enabling the transport of other molecules or particles to bones.

Trichloroisocyanuric acid (1,3,5-trichloro-1,3,5-triazine-2,4,6(1H,3H,5H)-tri-one or TCCA) is an N-halo compound which has been known since 1902. It has been used primarily as a disinfectant in swimming pools and water treatment as bleaching agent and bactericide. Recently, TCCA has become attractive candidate as a homogeneous catalyst in organic transformations due to its lack of volatility, commercial availability, low cost and ease of handling. And is also used as a bleaching agent in the textile industry

Sodium anthranilate is an excipient (pharmacologically inactive substance). Sodium anthranilate (Aminobenzoate sodium ,C7H6NNaO2), also known as sodium 2-aminobenzoate, is an organic amine. Aminobenzoate sodium exists as a yellow powder for use in pharmaceutical processing.

Tazanolast, an anti-allergic and anti-asthmatic agent with selective mast-cell stabilising effects, was developed jointly by Wakamoto and Torii Pharmaceuticals.

Cefetamet pivoxil is an oral third-generation cephalosporin which is hydrolysed to form the active agent, cefetamet. Cefetamet has excellent in vitro activity against the major respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis and group A beta-haemolytic streptococci; it is active against beta-lactamase-producing strains of H. influenzae and M. catarrhalis, but has poor activity against penicillin-resistant S. pneumoniae. Cefetamet has marked activity against Neisseria gonorrhoeae and possesses a broad spectrum of activity against Enterobacteriaceae. Both staphylococci and Pseudomonas spp. are resistant to cefetamet. Cefetamet pivoxil has been investigated in the treatment of both upper and lower community-acquired respiratory tract infections and has demonstrated equivalent efficacy to a number of more established agents, namely cefaclor, amoxicillin and cefixime. In complicated urinary tract infections, cefetamet pivoxil showed similar efficacy to cefadroxil, cefaclor and cefuroxime axetil. Cefetamet pivoxil was effective in the treatment of otitis media, pneumonia, pharyngotonsillitis and urinary tract infections in children. Cefetamet is not extensively bound to plasma proteins. Cefetamet has a relatively small apparent volume of distribution consistent with that of other beta-lactam antibiotics. The absorption and disposition of cefetamet in human subpopulations [i.e. children, elderly (< 75 years of age), renal impairment, liver disease and patients taking concomitant drugs] have been studied extensively. Only impaired renal function appears to significantly alter the elimination of this drug. Cefetamet pivoxil exerts its bactericidal action by inhibition the final transpeptidation step of peptidoglycan synthesis in the bacterial cell wall by binding to one or more of the Penicillin-binding Proteins (PBPs).

The topical anesthesic action of DIETHYLAMINOETHYL DIPHENYLHYDROXYPROPIONATE to rabbit cornea was assumed to be almost the same as lidocaine, DIETHYLAMINOETHYL DIPHENYLHYDROXYPROPIONATE showed a transitory hypotensive action on the blood presesure of a dog.

Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. It has anti-inflammatory properties different from the classical NSAID. Alminoprofen possesses both antiphospholipase A2 (PLA2) activity and anti-cycloxygenase (COX) activity.

Cefcapene is a semisynthetic third-generation cephalosporin with antibacterial activity. Cefcapene binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.